Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? ; volume:19 ; number:1 ; day:7 ; month:1 ; year:2020 ; pages:1-7 ; date:12.2020
Cardiovascular diabetology ; 19, Heft 1 (7.1.2020), 1-7, 12.2020
- Urheber
-
Yurista, Salva R.
Silljé, Herman H. W.
Rienstra, Michiel
Boer, Rudolf A. de
Westenbrink, B. Daan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-019-0984-0
- URN
-
urn:nbn:de:101:1-2020041321594973944870
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yurista, Salva R.
- Silljé, Herman H. W.
- Rienstra, Michiel
- Boer, Rudolf A. de
- Westenbrink, B. Daan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials